Legend Biotech Reports Second Quarter 2026 Results and Recent Highlights
Legend Biotech Corporation reported strong second quarter 2026 results highlighted by a 50% increase in net trade sales of CARVYKTI to approximately $657 million, expanded global availability, and positive clinical proof-of-concept data for its in vivo CAR-T therapy LB2501. The company strengthened its balance sheet with a $212 million public offer…